GBS (NYSE:GBS) vs. INVO Fertility (NASDAQ:IVF) Head to Head Survey

INVO Fertility (NASDAQ:IVF) and GBS (NYSE:GBS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Institutional & Insider Ownership

12.0% of INVO Fertility shares are held by institutional investors. Comparatively, 2.8% of GBS shares are held by institutional investors. 0.6% of INVO Fertility shares are held by company insiders. Comparatively, 0.3% of GBS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares INVO Fertility and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Fertility	-417.02%	N/A	-92.42%
GBS	N/A	-85.64%	-54.42%

Earnings and Valuation

This table compares INVO Fertility and GBS”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Fertility	$6.53 million	0.49	-$9.10 million	($630.30)	0.00
GBS	N/A	N/A	-$8.31 million	($0.56)	-1.00

GBS has lower revenue, but higher earnings than INVO Fertility. GBS is trading at a lower price-to-earnings ratio than INVO Fertility, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings for INVO Fertility and GBS, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Fertility	1	0	0	0	1.00
GBS	0	0	0	0	0.00

Volatility and Risk

INVO Fertility has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.

Summary

INVO Fertility beats GBS on 7 of the 11 factors compared between the two stocks.

About INVO Fertility

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.